Vivani Medical Mergers and Acquisitions Presentation Deck
Guaranteed adherence is
expected to deliver improved
health outcomes
Drug Substance + Administration = Drug Product
• Varying levels of adherence are
associated with different health
outcomes
• Different health outcomes may not be
attributable to drug substance alone
The American Diabetes Association
(ADA) Standard of Care guidelines
encourage treatment options that
address adherence
*NPM-119 - investigational candidate, not approved in any market
Drug
Substance
exenatide
(GLP-1 Receptor Agonist)
dulaglutide
(GLP-1 Receptor Agonist)
semaglutide
(GLP-1 Receptor Agonist)
exenatide
(GLP-1 Receptor Agonist)
Administration
Weekly BYDUREON"
Injection
Weekly
Injection
Drug
Product
Weekly
Injection trulicity.
Daily
Pill
6-Month
Implant
once weekly
OZEMPİC
semaglutide injection g
RYBELSUS
semaglutide tablets
NPM-119*
14View entire presentation